FY2025 Earnings Estimate for LRMR Issued By Lifesci Capital

Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Stock analysts at Lifesci Capital issued their FY2025 earnings estimates for Larimar Therapeutics in a research report issued on Monday, June 23rd. Lifesci Capital analyst C. Jubinville forecasts that the company will post earnings of ($1.84) per share for the year. The consensus estimate for Larimar Therapeutics' current full-year earnings is ($1.15) per share.

LRMR has been the topic of several other reports. Wedbush dropped their target price on Larimar Therapeutics from $17.00 to $15.00 and set an "outperform" rating on the stock in a research report on Tuesday. Robert W. Baird dropped their price objective on Larimar Therapeutics from $13.00 to $10.00 and set an "outperform" rating on the stock in a report on Tuesday, March 25th. Guggenheim reaffirmed a "buy" rating and set a $26.00 price objective on shares of Larimar Therapeutics in a research report on Tuesday. Citigroup reiterated a "buy" rating on shares of Larimar Therapeutics in a research note on Tuesday, March 25th. Finally, HC Wainwright increased their price target on shares of Larimar Therapeutics from $15.00 to $16.00 and gave the stock a "buy" rating in a research note on Tuesday, March 25th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $18.50.

Larimar Therapeutics Trading Up 8.7%

Shares of NASDAQ:LRMR opened at $3.25 on Thursday. The firm has a market cap of $208.10 million, a price-to-earnings ratio of -2.18 and a beta of 0.79. Larimar Therapeutics has a 1 year low of $1.61 and a 1 year high of $11.20. The business has a fifty day simple moving average of $2.37 and a 200 day simple moving average of $2.96.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last issued its earnings results on Wednesday, April 30th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.04).

Institutional Investors Weigh In On Larimar Therapeutics

A number of large investors have recently added to or reduced their stakes in LRMR. Janus Henderson Group PLC raised its position in shares of Larimar Therapeutics by 15.7% in the fourth quarter. Janus Henderson Group PLC now owns 6,443,286 shares of the company's stock valued at $24,936,000 after purchasing an additional 876,431 shares during the period. Blue Owl Capital Holdings LP grew its stake in Larimar Therapeutics by 11.7% in the 4th quarter. Blue Owl Capital Holdings LP now owns 4,653,040 shares of the company's stock valued at $18,007,000 after buying an additional 486,211 shares during the last quarter. Alyeska Investment Group L.P. grew its stake in Larimar Therapeutics by 46.6% in the 1st quarter. Alyeska Investment Group L.P. now owns 1,442,473 shares of the company's stock valued at $3,101,000 after buying an additional 458,396 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in Larimar Therapeutics by 23.5% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,100,000 shares of the company's stock worth $8,127,000 after acquiring an additional 399,123 shares during the period. Finally, Nuveen LLC acquired a new position in Larimar Therapeutics during the 1st quarter worth $376,000. Institutional investors own 91.92% of the company's stock.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.